File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure

TitleLive-donor liver transplantation for acute-on-chronic hepatitis B liver failure
Authors
Issue Date2003
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com
Citation
Transplantation, 2003, v. 76 n. 8, p. 1174-1179 How to Cite?
AbstractBackground. The survival results of patients demonstrating acute-on-chronic liver failure and undergoing live-donor liver transplantation (LDLT) have been reported to be poor. This study evaluates the survival outcomes of patients who underwent LDLT using right-lobe liver grafts for acute-on-chronic hepatitis B liver failure. Methods. The study comprised 32 patients who demonstrated acute-on-chronic hepatitis B liver failure with mean (± standard error of mean) Model for End. Stage Liver Disease scores of 36±1.8. The mean preoperative intensive care unit stay was 2.4 days. LDLT using a right-lobe liver graft including the middle hepatic vein was performed in all patients. Oral lamivudine 100 mg daily was used for hepatitis B prophylaxis. Results. The patients received liver grafts that were 52%±2% of the estimated standard liver weight. Hospital mortality occurred in two patients, and two other patients died on follow-up. At a median follow-up of 23 months, both patient and graft survival rates were 88%. The survival results were not different from those of 49 patients who underwent right-lobe LDLT for elective conditions during the same study period (graft survival=82%, P=0.55; patient survival=84%, P=0.75). Two (6.3%) patients developed hepatitis B virus DNA breakthrough 47 and 53 months, respectively, after transplantation, but they remained well after treatment with adefovir. Conclusion. Right-lobe LDLT is an effective therapeutic option for patients with acute-on-chronic hepatitis B liver failure. It results in satisfactory survival outcomes comparable to those in patients undergoing LDLT for elective conditions.
Persistent Identifierhttp://hdl.handle.net/10722/76257
ISSN
2015 Impact Factor: 3.69
2015 SCImago Journal Rankings: 1.699
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLiu, CLen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorWei, WIen_HK
dc.contributor.authorYong, BHen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorWong, Jen_HK
dc.date.accessioned2010-09-06T07:19:18Z-
dc.date.available2010-09-06T07:19:18Z-
dc.date.issued2003en_HK
dc.identifier.citationTransplantation, 2003, v. 76 n. 8, p. 1174-1179en_HK
dc.identifier.issn0041-1337en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76257-
dc.description.abstractBackground. The survival results of patients demonstrating acute-on-chronic liver failure and undergoing live-donor liver transplantation (LDLT) have been reported to be poor. This study evaluates the survival outcomes of patients who underwent LDLT using right-lobe liver grafts for acute-on-chronic hepatitis B liver failure. Methods. The study comprised 32 patients who demonstrated acute-on-chronic hepatitis B liver failure with mean (± standard error of mean) Model for End. Stage Liver Disease scores of 36±1.8. The mean preoperative intensive care unit stay was 2.4 days. LDLT using a right-lobe liver graft including the middle hepatic vein was performed in all patients. Oral lamivudine 100 mg daily was used for hepatitis B prophylaxis. Results. The patients received liver grafts that were 52%±2% of the estimated standard liver weight. Hospital mortality occurred in two patients, and two other patients died on follow-up. At a median follow-up of 23 months, both patient and graft survival rates were 88%. The survival results were not different from those of 49 patients who underwent right-lobe LDLT for elective conditions during the same study period (graft survival=82%, P=0.55; patient survival=84%, P=0.75). Two (6.3%) patients developed hepatitis B virus DNA breakthrough 47 and 53 months, respectively, after transplantation, but they remained well after treatment with adefovir. Conclusion. Right-lobe LDLT is an effective therapeutic option for patients with acute-on-chronic hepatitis B liver failure. It results in satisfactory survival outcomes comparable to those in patients undergoing LDLT for elective conditions.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.comen_HK
dc.relation.ispartofTransplantationen_HK
dc.rightsTransplantation. Copyright © Lippincott Williams & Wilkins.en_HK
dc.subject.meshAcute Diseaseen_HK
dc.subject.meshAdenine - analogs & derivatives - therapeutic useen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshDNA, Viral - metabolismen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFollow-Up Studiesen_HK
dc.subject.meshGraft Survivalen_HK
dc.subject.meshHepatitis B - complicationsen_HK
dc.subject.meshHepatitis B virus - geneticsen_HK
dc.subject.meshHepatitis B, Chronic - complicationsen_HK
dc.subject.meshHospital Mortalityen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLiver Failure - etiology - surgeryen_HK
dc.subject.meshLiver Transplantation - mortalityen_HK
dc.subject.meshLiving Donorsen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPhosphonic Acidsen_HK
dc.subject.meshRetrospective Studiesen_HK
dc.subject.meshSurvival Analysisen_HK
dc.titleLive-donor liver transplantation for acute-on-chronic hepatitis B liver failureen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0041-1337&volume=76&spage=1174&epage=1179&date=2003&atitle=Live-donor+liver+transplantation+for+acute-on-chronic+hepatitis+B+liver+failureen_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailWei, WI: hrmswwi@hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailWong, J: jwong@hkucc.hku.hken_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityWei, WI=rp00323en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityWong, J=rp00322en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/01.TP.0000087341.88471.E5en_HK
dc.identifier.pmid14578749-
dc.identifier.scopuseid_2-s2.0-0242268932en_HK
dc.identifier.hkuros87527en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0242268932&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume76en_HK
dc.identifier.issue8en_HK
dc.identifier.spage1174en_HK
dc.identifier.epage1179en_HK
dc.identifier.isiWOS:000186269600007-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLiu, CL=7409789712en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridWei, WI=7403321552en_HK
dc.identifier.scopusauthoridYong, BH=7003644314en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridWong, J=8049324500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats